The long-term outcomes of deceased-donor liver transplantation for primary biliary cirrhosis: A two-center study in China

Lin Chen 1, Xiaodong Shi 2, Guoyue Lv 3, Xiaodong Sun 3, Chao Sun 4, Yanjun Cai 1, Junqi Niu 1, Jinglan Jin 1, Ning Liu 5, Wanyu Li 1Corresp. 1

1 Department of Hepatology, First Hospital, Jilin University, Changchun, China
2 Department of Rheumatology, First Hospital, Jilin University, Changchun, China
3 Department of Hepatobiliary Pancreatic Surgery, First Hospital, Jilin University, Changchun, China
4 Department of Transplant Center, First Central Hospital, Tianjin, Tianjin, China
5 Department of Cardiology, First Hospital, Jilin University, Changchun, China

Corresponding Author: Wanyu Li
Email address: liwanyu2006@163.com

Background & Aims: Factors that influence the outcomes after deceased-donor liver transplantation (DDLT) for primary biliary cirrhosis (PBC) are not well known. We aimed to clarify these effects on the outcomes after DDLT. Methods: We retrospectively analyzed patients with PBC who underwent DDLT from March 2006 to July 2018 at the organ transplantation center of the First Hospital of Jilin University and the First Central Hospital of Tianjin. Changes in liver function were assessed posttransplantation. Recurrence, survival rate, and complications were recorded at follow-up. The effect of liver transplantation on survival and recurrence was evaluated using univariate and/or multivariate Cox regression analyses. Results: In total, 69 patients with PBC undergoing DDLT were included in this study. At 4 weeks posttransplant, all liver function tests were normal. During a median follow-up time of 32 months, 5-year overall survival and recurrence rates were estimated as 95.1% and 21.8%, respectively. A recipient aspartate aminotransferase-to-platelet ratio index (APRI) greater than 2 was negatively associated with survival (P = 0.0018). Multivariate regression analysis demonstrated that age younger than 48 years was an independent risk factor for recurrent PBC in recipients undergoing liver transplantation (hazard ratio 0.028, 95% confidence interval 0.01-0.71, P = 0.03). Posttransplant infections (62%) and biliary tract complications (26%) were the most common complications. Conclusion: Liver transplantation is an effective treatment for patients with PBC. Liver function normalizes by 4 weeks posttransplant. Although posttransplant survival rate is high, recurrence is possible. To some extent, survival rate and recurrence rate can be predicted by APRI and age, respectively.
The Long-term Outcomes of Deceased-donor Liver Transplantation for Primary Biliary Cirrhosis: A Two-center Study in China

Lin Chen, MD\textsuperscript{1,\S}, Xiaodong Shi, PhD\textsuperscript{2,\S}, Guoyue Lv, PhD\textsuperscript{3}, Xiaodong Sun, PhD\textsuperscript{3}, Chao Sun, PhD\textsuperscript{4}, Yanjun Cai, MD\textsuperscript{1}, Junqi Niu, PhD\textsuperscript{1}, Jinglan Jin, PhD\textsuperscript{1}, Ning Liu, MD\textsuperscript{5}, Wanyu Li, PhD\textsuperscript{1,*}

Department of Hepatology, First Hospital, Jilin University, Changchun 130021, China

1 Department of Hepatology, First Hospital, Jilin University, No. 71 Xinmin Street, Changchun 130021, China.

2 Department of Rheumatology, First Hospital, Jilin University, No. 71 Xinmin Street, Changchun 130021, China.

3 Department of Hepatobiliary Pancreatic Surgery, First Hospital, Jilin University, No. 71 Xinmin Street, Changchun 130021, China.

4 Department of Transplant Center, First Central Hospital, Tianjin, No. 24 Fukang Road, Tianjin 300192, China.

5 Department of Cardiology, First Hospital, Jilin University, No. 71 Xinmin Street, Changchun 130021, China.

\S Lin Chen and Xiaodong Shi contributed equally to this work.

*Correspondence to:

Dr. Wanyu Li

Department of Hepatology, First Hospital, Jilin University, No. 71 Xinmin Street, Changchun
130021, China.

Email address: corresponding_author_liwanyu2006@163.com
Abstract

Background & Aims: Factors that influence the outcomes after deceased-donor liver transplantation (DDLT) for primary biliary cirrhosis (PBC) are not well known. We aimed to clarify these effects on the outcomes after DDLT.

Methods: We retrospectively analyzed patients with PBC who underwent DDLT from March 2006 to July 2018 at the organ transplantation center of the First Hospital of Jilin University and the First Central Hospital of Tianjin. Changes in liver function were assessed posttransplantation. Recurrence, survival rate, and complications were recorded at follow-up. The effect of liver transplantation on survival and recurrence was evaluated using univariate and/or multivariate Cox regression analyses.

Results: In total, 69 patients with PBC undergoing DDLT were included in this study. At 4 weeks posttransplant, all liver function tests were normal. During a median follow-up time of 32 months, 5-year overall survival and recurrence rates were estimated as 95.1% and 21.8%, respectively. A recipient aspartate aminotransferase-to-platelet ratio index (APRI) greater than 2 was negatively associated with survival ($P = 0.0018$). Multivariate regression analysis demonstrated that age younger than 48 years was an independent risk factor for recurrent PBC in recipients undergoing liver transplantation (hazard ratio 0.028, 95% confidence interval 0.01-0.71, $P = 0.03$). Posttransplant infections (62%) and biliary tract complications (26%) were the most common complications.

Conclusion: Liver transplantation is an effective treatment for patients with PBC. Liver function normalizes by 4 weeks posttransplant. Although posttransplant survival rate is high, recurrence is possible. To some extent, survival rate and recurrence rate can be predicted by APRI and age, respectively.

Keywords: PBC, Liver transplantation, APRI, rPBC, Liver function
**Introduction**

Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized by the immune-mediated destruction of intrahepatic bile ducts, resulting in fibrosis, cirrhosis, and ultimately, liver failure (Lindor 2007). PBC primarily affects middle-aged women and is diagnosed by the presence of biochemical markers for cholestasis and highly specific serological antimitochondrial antibodies (AMAs) as well as histologically progressive, nonsuppurative, destructive cholangitis affecting small and medium bile ducts (Selmi et al. 2011). Without therapy, the median survival of patients with PBC is reported as 7.5 years in symptomatic patients and 16 years in asymptomatic patients (Lee & Kaplan 2005). The use of ursodeoxycholic acid (UDCA) is effective in improving liver function, slows the progression of liver fibrosis, and significantly reduces the need for liver transplantation. Up to 40% of patients with PBC do not adequately respond to UDCA monotherapy (Akamatsu & Sugawara 2012). Obeticholic acid (OCA) as a second-line treatment for PBC patients with incomplete ursodeoxycholic acid response; however, approximately 50% of patients might need other treatments to achieve treatment goals (Shah & Kowdley 2019). Therefore, liver transplantation is the only effective treatment for patients with advanced PBC.

When compared with large European series, where PBC constituted about 9% of all liver transplantation (Schoning et al. 2015), PBC accounts for a relatively low proportion (3.5%) in this Asian series (Sun et al. 2011). The prognosis of liver transplantation for patients with PBC is favorable compared with other indications. In Western countries, overall patient survival from liver transplantation for PBC was 93–94% at 1 year, 90–91% at 3 years, and 82–86% at 5 years (Liberal et al. 2013). However, posttransplant survival rates for alcohol-associated liver cirrhosis and hepatic failure are lower than those for PBC (86%, 73%, and 59% for alcohol-associated liver cirrhosis and 70%, 64%, and 58% for hepatic failure at 1, 5, and 10 years, respectively) (Adam et al. 2012).

Recurrent PBC (rPBC) after liver transplantation was first documented in 1982 (Neuberger et al. 1982). With the development of surgical techniques, transplant organ storage, and immunosuppressants, the posttransplant survival rate for PBC has improved. However, with
extensions in survival, rPBC is not uncommon. In a Japanese multicenter study with 444 patients
with PBC, relapse rates of PBC posttransplant were 9.6%, 20.6%, and 40.4% at 5, 10, and 15 years,
respectively (Egawa et al. 2016). Recurrent disease itself rarely affects patient and graft survival in
short- and medium-term follow-up. However, in the long term, rPBC may have a negative impact
on patient and graft survival. One study reports that recurrent PBC results in graft loss at a rate of
1.0–5.4% (Carrion & Bhamidimarri 2013). Despite improved survival rates, certain complications
can still affect posttransplant prognosis. Our study aimed to report the long-term outcomes of
deceased-donor liver transplantation (DDLT) in patients with PBC in northern China.

Patients and Methods

Patients

We retrospectively studied data from all 69 patients who underwent DDLT for PBC from March
2006 to July 2018 at the organ transplantation center of the First Hospital of Jilin University and
the First Central Hospital of Tianjin. The diagnosis of PBC is based on established diagnostic
criteria of EASL guidelines (2017). The 69 patients received UDCA therapy (13–15 mg/kg/day)
pre- and post-transplant, and had no OCA and immunosuppressisve treatment preoperatively. The
AMAs of 69 patients were all postive before liver transplantation. We declare that this study has
been approved by the Ethics Committee of the First Hospital of Jilin University and the First
Central Hospital of Tianjin, written informed consent was obtained from all participants.

Calculation formulas

The model for end-stage liver disease (MELD) score was calculated using the following formula:

\[ R = 3.8 \times \ln(\text{bilirubin in mg/dl}) + 11.2 \times \ln(\text{international normalized ratio}) + 9.6 \times \ln(\text{creatinine in mg/dl}) + 6.4 \times \text{etiology (etiology: 0 for cholestatic or alcohol-related liver disease; 1 for others)}) \]

And, the formula for aspartate aminotransferase-to-platelet ratio index (APRI): \( R = (\text{aspartate aminotransferase/ the upper limits of normal}) \times 100/ (\text{platelet count in } 10^9/L) \). The updated Mayo risk score (Murtaugh et al. 1994) was calculated by the formula: \( R = 6.843 + 0.051 \times \text{[age]} + 1.029 \times \ln(\text{bilirubin in mg/dl}) + 1.020 \times \ln(\text{international normalized ratio}) - 3.304 \times \ln(\text{albumin in mg/dl}) \)
Liver biopsy was performed when patients had unexplainable abnormal liver function post-transplant. The diagnosis of acute transplant rejection and chronic transplant rejection were based on the international Banff schema (Demetris et al. 2000). Recurrent PBC was diagnosed when either of the following findings were observed: (i) granulomatous cholangitis or epithelioid granulomas without any sign of infection or (ii) dense lymphoid aggregates in the portal tracts not associated with perivenular inflammation or endotheliitis (Haga et al. 2007).

Serologic liver function
For each patient, liver function tests [aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), total bilirubin (TBIL), direct bilirubin (DBIL), albumin (ALB)] were performed immediately before the transplant, daily for 4 days after the transplant, and weekly for 4 weeks posttransplant. If AST or/and ALT was greater than 1500 U/L at 1 week after transplant, it was classified as initial poor graft function (IPGF) (Kocbiyik et al. 2009). Of the initial 69 patients, 5 patients were excluded from the analysis of liver function results (5 due to uncompleted data). In total, the liver function results of 64 patients were analyzed.

Diagnosis of complications
Complications were diagnosed based on symptoms, laboratory results, and radiological findings. Infection-related complications were diagnosed based on established diagnostic criteria (Horan et al. 2008). Infections can be classified by anatomy (such as respiratory system, renal system, biliary system) or by microbiology (such as bacteria, fungus, virus). In this study, most infection complications were based on diagnostic microbiology; some infection complications with negative diagnostic microbiology were diagnosed based on clinical presentation and radiology.

Biliary complications included strictures (anastomotic and nonanastomotic), leakage, and bile
tumors. Anastomotic stricture was diagnosed as a segmental stricture located within 1 cm of the biliary anastomosis as shown by magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangiopancreatography (ERCP), or percutaneous cholangiography. Ischemic-type biliary lesions were diagnosed when either MRCP or ERCP showed typical signs of segmental or diffuse intrahepatic or extrahepatic strictures or biliary tree destruction. Biliary leakage was determined by abdominal fluid drainage tube or bile drainage under ultrasound-guided puncture. Color Doppler ultrasound was performed the second day after liver transplant or with abnormal liver function. Abdominal computed tomography with contrast or angiography was performed when complications of the portal vein or hepatic artery were detected by color Doppler ultrasound.

Diabetes mellitus was defined as a fasting glucose higher than 7 mmol/L or a random glucose higher than 11.1 mmol/L and a hemoglobin A1C higher than 6.5%.

Statistical analysis

Descriptive statistics are presented as median and range for continuous variables and counts and percentages for categorical variables. Overall survival and PBC recurrence-free curves were estimated according to the Kaplan-Meier method. The log-rank test was used to evaluate whether each variable significantly affected postoperative patient survival and PBC recurrence. The hazard ratio and 95% confidence interval were calculated by multivariate Cox regression analysis. A P-value of 0.05 was considered to be statistically significant.

Results

Patient Characteristic

In our study, the follow-up period ranged from 0.5 to 107 (median, 32) months. The baseline characteristics of the 69 patients are summarized in Table 1. The median age was 55 years (range, 39–67), and 60 patients (87%) were female. The MELD and APRI were 19 (range, 6–31) and 2.26 (range, 0.11–42.22), respectively. The median updated Mayo risk score was 9.53 (range, 4.34–12.44). The median levels of AST and ALT were 75 (range, 15–513) and 45 (range, 6-229),
respectively. The median ALP and GGT levels were 186.5 (range, 54–732) and 93.5 IU/L (range, 14–779), respectively. The median value of TBIL was 9.83 (range, 0.41–41.6 mg/dl). The median value of ALB was 3 g/dl (range, 2.3–4).

Of these cases, 26 patients were classified as Child-Pugh grade B; 43 patients, grade C. One patient had a second liver transplant due to thrombosis of the hepatic artery 2 weeks after the first liver transplant.

**APRI greater than 2 associated with poor survival of PBC patient survival after liver transplantation**

During the follow-up, three patients died. One died from abdominal hemorrhage after transplant, and the other two died from infection and liver failure at 14 months posttransplantation. Overall patient survival in the study population was 98.6% at 1 year, 95.1% at 3 years, and 95.1% at 5 years after transplantation(Fig. 1). Multivariate Cox regression analysis were failed to perform due to the small samples of death. A log-rank test of the Kaplan-Meier life table analysis showed that a pre-transplant APRI greater than 2 was related to poor survival ($P = 0.0018$) (Fig. 2). The Kaplan-Meier life table analysis with a log-rank test failed to find that age, gender, the MELD score, Child-Pugh score, Mayo risk score, pre- and post-operative liver function were statistically significant in predicting the survival of liver transplantation.

**Younger age at liver transplantation associated with a greater risk for recurrent PBC**

Of 69 patients, 7 patients who had unexplained abnormal liver function underwent percutaneous liver biopsy postoperatively. Only 1 patient was diagnosed rejection reaction, and another 6 patients were diagnosed recurrent PBC. The incidence of recurrence increased with time after transplantation (Fig. 3), leading to relapse rates of 3.5% at 1 year, 8.1% at 3 years, and 21.8% at 5 years after transplantation. The median duration from liver transplantation to the diagnosis of recurrent was 21.5 months. The Kaplan-Meier life table analysis with a log-rank test revealed a preoperative factor of recipients aged 48 years or younger as the only significant risk factor of disease recurrence (Fig. 4). In a multivariate Cox regression analyse model adjusted for gender, pre-operative Mayo risk score, APRI score, MELD score, a preoperative age of 48 years or
younger remained the only independent risk factor of patient recurrence (hazard ratio 0.028, 95% confidence interval 0.01-0.71, \( P = 0.03 \))

**Normal liver function at 4 weeks posttransplantation**

The curves of AST and ALT changes posttransplantation were similar—reaching a peak on the first day, dramatically decreasing on the second day (AST declined more than ALT), returning to normal by 1 week, and remaining stable with normal levels at 4 weeks (Fig. 5a). The curves of ALP and GGT changes were also somewhat similar after transplant (Fig. 5b)—both returned to normal on the first day but then slowly increased. However, ALP peaked at the seventh day and then returned to the normal range; GGT peaked at 2 weeks (2 times higher than the upper cutoff) and then slowly decreased to normal by 4 weeks.

The levels of TBIL and direct bilirubin (DBIL) decreased after transplantation to normal by 4 weeks (Fig. 5c). The level of ALB eventually increased to normal by 4 weeks (Fig. 5d). The peak levels of ALT and/or AST were greater than 1500 U/L in 15 patients. The frequency of IPGF was 21.7%.

**Infection and biliary complications**

Postoperative complications of the 69 patients are summarized in Table 2. A total of 43 patients (62%) developed 63 episodes of infections in our follow-up period. Of these patients, 16 developed multiple infectious complications. The vast majority of infections were microbiological infection. Among the cases of infection without evidence of microbiology, there were four cases of pneumonia, one upper respiratory infection, one bile duct infection, and one urinary infection. The 56 microbiologically defined episodes were categorized by the following causes: 42 (75%), bacteria; 6 (11%), fungus; 6 (11%), mixture of bacteria and fungus; and 2 (4%), virus.

During the follow-up, 18 (26%) patients had biliary complications, including 7 anastomotic strictures (10%), 10 nonanastomotic strictures (14%), 3 leakage (4.3%), and 1 biloma (1.5%). One patient had biliary leakage and nonanastomotic strictures; two patients had anastomotic strictures secondary to leakage. Among the five patients with vascular complications, two (2.9%) had portal vein thrombosis, and three (4.3%) had hepatic artery thrombosis. One patient had a second liver
transplant due to liver failure caused by nonanastomotic strictures secondary to hepatic artery thrombosis. Only one (69) patient had a rejection reaction, which occurred at 33 months. Other complications included osteoporosis (5), hepatitis B infection (3), and diabetes (2).

Discussion

Prognosis is favorable for patients with PBC after liver transplantation. Among our patients who underwent DDLT for PBC, the causes of mortality were abdominal hemorrhage, infection and liver failure. The 1- and 3-year survival rates were 98.6% and 95.1%, respectively, after liver transplantation. In a retrospective study of the United Network for Organ Sharing database, patient survival at 1, 3, and 5 years for living donor liver transplantation was 95.5%, 93.6%, and 92.5% and for dead donor liver transplantation was 90.9%, 86.5%, and 84.9%, respectively (Kashyap et al. 2010). Compared with previously reported outcomes, overall survival was higher in our series. Several inconsistencies remain regarding factors prognostic of patient survival after liver transplantation among various cohorts. Similar to Bhat’s research, we found that an APRI greater than 2 is a negative predictor of patient survival after liver transplantation for PBC (Bhat et al. 2015). Therefore, APRI could be of clinical use to predict survival rate.

AMA is not a good marker for rPBC because it frequently remains positive after transplantation (Dubel et al. 1995). Thus, liver puncture biopsy is the gold diagnostic standard for rPBC. Due to different diagnostic criteria and the use of protocol biopsies by transplant programs, the reported relapse rates of PBC range from 1% to 53% (Akamatsu & Sugawara 2012; Bosch et al. 2015). In our study, recurrence rate increased after transplant as recurrence risks grew: 3.5% at 1 year, 8.1% at 3 years, and 21.8% at 5 years. These findings are consistent with those of previous studies (Charatcharoenwitthaya et al. 2007). However, other studies found a higher recurrence risk when asymptomatic patients had regular protocol biopsies. Unlike biopsies performed only after identifying liver dysfunction, regular protocol biopsies can detect potential recurrence before dysfunction occurs (Charatcharoenwitthaya et al. 2007). Therefore, more rPBCs can be detected by protocol biopsies. However, the effect of recurrent disease on the outcome of patients who
performed liver transplantation for PBC is uncertain (Akamatsu & Sugawara 2012), whether patients can benefit from protocol biopsies needs further study. Previous studies have identified several factors associated with rPBC, including age, number of HLA mismatches, and the use of immunosuppressants. However, the association between age and recurrence is still being debated (Charatcharoenwitthaya et al. 2007). Consistent with our study’s findings, a Japanese study indicated that recipients younger than 48 years are at risk for recurrence (Egawa et al. 2016). However, the mechanism involved remains unknown.

After liver transplantation, liver function recovered by 4 weeks; ALT and AST activities each peaked once before this recovery. In a retrospective study of 75 liver transplant patients, transaminase activities reached 10–12 times above the upper limits of normal on the first day after surgery and reached a normal range by the ninth day, similar to our results. These findings suggest that the early peaks of transaminase activity represent preservative damage during liver removal from the donor and subsequent ischemia-reperfusion injury during transplantation (Naik et al. 2013). In our study, the frequency of IGPF was 21.7%, which was lower than that in other studies (29.5%) (Chui et al. 2000). Different from the ALP curve, GGT levels increased until peaking at the seventh day, whereas ALP levels increased until peaking at the second week, and in both cases the levels then decreased until reaching the normal range by the first month. A previous study reports that GGT levels increase to a maximum at day 9 after surgery and then decrease. This previous study showed that the post-operative GGT level was significantly associated with the survival of liver transplantation. Our study failed to find that pre/post-operative GGT level was statistically associated with the outcome of liver transplantation. The early elevation in GGT after liver transplantation may produced by ischemia-reperfusion and surgical stress in the recipient (Zhang et al. 2007). The levels of TBIL and DBIL decreased after transplantation to normal by 4 weeks. Bilirubin is a distinct predictive biomarker for liver function recovery. Dynamic monitoring of bilirubin is helpful for early detection of biliary complications.

Despite advances in surgical techniques, organ preservation, immunosuppression, and infection prevention, various complications still affect a patient’s prognosis, including infections, biliary
complications, vascular complications, and rejections. In our study, the frequencies of infection and biliary complications were 62% and 21%, respectively. Bacterial infection was the most common complication, consistent with other studies (Li et al. 2012; Vera et al. 2011). Thus, the biggest problem is controlling infection to decrease posttransplant complications. Biliary complications are the primary morbidity in liver transplant patients, have an incidence of 10–30%, and even cause mortality (Mejia et al. 2016; Wojcicki et al. 2008), consistent with the 26% incidence of biliary tract in our study. The similarity of these results suggests that even though PBC affects small bile ducts, biliary complications have not dramatically increased. Timely diagnosis and aggressive treatment are vital for the survival of patients and grafts (Khalaf 2010). Thrombosis of the hepatic artery is a fatal vascular complication with a rate of 3–5% and usually requires re-transplantation, with a high mortality incidence of 20–60% (Khalaf 2010; Ma et al. 2016). In our study, 3 (4.3%) patients had thromboses of the hepatic artery, and 2 (2.9%) had portal vein thrombosis, consistent with previous studies (Khalaf 2010).

One of limitation in this study is the review of liver pathology. Liver biopsy was performed when patients had unexplainable abnormal liver function rather than protocol biopsies in this study, so early recurrence of PBC in our patients may have been missed. In future researches, protocol criteria may detect early recurrence timely. Another limitation is that the small samples of patients does not allow multivariate analysis of survival. In the future, when the the number of sample increases, we will further analyze the risk factors of survival.

In conclusion, liver transplantation is an effective treatment for patients with PBC due to its excellent postoperative survival rate. After transplantation, liver function recovers well with decreased infection and biliary complications. With advances in the technique, the survival rate after transplantation has become very high, but rPBC is not rare and is related to patient age. To some extent, APRI can be used to predict a patient’s survival.

ADDITIONAL INFORMATION AND DECLARATIONS
This study was supported by grants from the First Hospital of Jilin University (NO. JDYYJC006), Tianqing Liver Disease Research Fund (NO. TQGB20180160), Department of Science and Technology of Jilin Province (NO.20180520116JH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests
The authors declare there are no competing interests.

Human Ethics
We declare that this study has been approved by the Ethics Committee of the First Hospital of Jilin University and the First Central Hospital of Tianjin.

References

2017. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. *Journal of Hepatology* 67:145-172 DIO 10.1016/j.jhep.2017.03.022

Adam R, Karam V, Delvart V, O'Grady J, Mirza D, Klemplnauer J, Castaing D, Neuhaus P, Jamieson N, Salizzoni M, Pollard S, Lerut J, Paul A, Garcia-Valdecasas JC, Rodriguez FS, and Burroughs A. 2012. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). *Journal of Hepatology* 57:675-688 DIO 10.1016/j.jhep.2012.04.015

Akamatsu N, and Sugawara Y. 2012. Primary biliary cirrhosis and liver transplantation. *Intractable Rare Dis Res* 1:66-80 DIO 10.5582/irdr.2012.v1.2.66
Bhat M, Ghali P, Rollet-Kurhajec KC, Bhat A, Wong P, Deschenes M, and Sebastiani G. 2015. Serum fibrosis biomarkers predict death and graft loss in liver transplantation recipients. *Liver Transplantation* 21:1383-1394 DIO 10.1002/lt.24217

Bosch A, Dumortier J, Maucort-Boulch D, Scoazec JY, Wendum D, Conti F, Morard I, Rubbia-Brandt L, Terris B, Radenne S, Abenavoli L, Poupon R, Chazouilleres O, Calmus Y, Boillot O, Giostra E, and Corpechot C. 2015. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. *Journal of Hepatology* 63:1449-1458 DIO 10.1016/j.jhep.2015.07.038

Carrion AF, and Bhamidimarri KR. 2013. Liver transplant for cholestatic liver diseases. *Clinics in Liver Disease* 17:345-359 DIO 10.1016/j.cld.2012.12.005

Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, Enders FT, Lindor KD, Krom RA, and Wiesner RH. 2007. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. *Liver Transplantation* 13:1236-1245 DIO 10.1002/lt.21124

Chui AK, Shi LW, Rao AR, Anasuya A, Hagl C, Pillay P, Verran D, McCaughan GW, and Sheil AG. 2000. Primary graft dysfunction after liver transplantation. *Transplantation Proceedings* 32:2219-2220.

Demetris A, Adams D, Bellamy C, Blakolmer K, Clouston A, Dhillon AP, Fung J, Gouw A, Gustafsson B, Haga H, Harrison D, Hart J, Hubscher S, Jaffe R, Khettry U, Lassman C, Lewin K, Martinez O, Nakazawa Y, Neil D, Pappo O, Parizhskaya M, Randhawa P, Rasoul-Rockenschaub S, Reinhold F, Reynes M, Robert M, Tsamandas A, Wanless I, Wiesner R, Wernerson A, Wrba F, Wyatt J, and Yamabe H. 2000. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. *Hepatology* 31:792-799 DIO
Dubel L, Farges O, Bismuth H, Sebagh M, Homberg JC, and Johanet C. 1995. Kinetics of anti-M2 antibodies after liver transplantation for primary biliary cirrhosis. *Journal of Hepatology* 23:674-680.

Egawa H, Sakisaka S, Teramukai S, Sakabayashi S, Yamamoto M, Umeshita K, and Uemoto S. 2016. Long-Term Outcomes of Living-Donor Liver Transplantation for Primary Biliary Cirrhosis: A Japanese Multicenter Study. *American Journal of Transplantation* 16:1248-1257 DIO 10.1111/ajt.13583

Haga H, Miyagawa-Hayashino A, Taira K, Morioka D, Egawa H, Takada Y, Manabe T, and Uemoto S. 2007. Histological recurrence of autoimmune liver diseases after living-donor liver transplantation. *Hepatology Research* 37 Suppl 3:S463-469 DIO 10.1111/j.1872-034X.2007.00245.x

Horan TC, Andrus M, and Dudeck MA. 2008. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. *American Journal of Infection Control* 36:309-332 DIO 10.1016/j.ajic.2008.03.002

Kashyap R, Safadjou S, Chen R, Mantry P, Sharma R, Patil V, Maloo M, Ryan C, Marroquin C, Barry C, Ramaraju G, Maliakkal B, and Orloff M. 2010. Living donor and deceased donor liver transplantation for autoimmune and cholestatic liver diseases--an analysis of the UNOS database. *Journal of Gastrointestinal Surgery* 14:1362-1369 DIO 10.1007/s11605-010-1256-1

Khalaf H. 2010. Vascular complications after deceased and living donor liver transplantation: a single-center experience. *Transplantation Proceedings* 42:865-870 DIO 10.1016/j.transproceed.2010.02.037

Kocbiyik A, Demirhan B, Sevmis S, Budakoglu I, Karakayali H, and Haberal M. 2009. Role of postreperfusion subcapsular wedge biopsies in predicting initially poor graft function after liver transplantation. *Transplantation Proceedings* 41:2747-2748 DIO 10.1016/j.transproceed.2009.07.003
Lee YM, and Kaplan MM. 2005. The natural history of PBC: has it changed? *Seminars in Liver Disease* 25:321-326

DIO 10.1055/s-2005-916323

Li C, Wen TF, Mi K, Wang C, Yan LN, and Li B. 2012. Analysis of infections in the first 3-month after living donor liver transplantation. *World Journal of Gastroenterology* 18:1975-1980 DIO 10.3748/wjg.v18.i16.1975

Liberal R, Zen Y, Mieli-Vergani G, and Vergani D. 2013. Liver transplantation and autoimmune liver diseases. *Liver Transplantation* 19:1065-1077 DIO 10.1002/lt.23704

Lindor K. 2007. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. *New England Journal of Medicine* 357:1524-1529 DIO 10.1056/NEJMct074694

Ma L, Lu Q, and Luo Y. 2016. Vascular complications after adult living donor liver transplantation: Evaluation with ultrasonography. *World Journal of Gastroenterology* 22:1617-1626 DIO 10.3748/wjg.v22.i4.1617

Mejia GA, Olarte-Parra C, Pedraza A, Rivera JB, and Benavides CA. 2016. Biliary Complications After Liver Transplantation: Incidence, Risk Factors and Impact on Patient and Graft Survival. *Transplantation Proceedings* 48:665-668 DIO 10.1016/j.transproceed.2016.02.033

Murtaugh PA, Dickson ER, Van Dam GM, Malinchoc M, Grambsch PM, Langworthy AL, and Gips CH. 1994. Primary biliary cirrhosis: prediction of short-term survival based on repeated patient visits. *Hepatology* 20:126-134.

Naik P, Sritharan V, Bandi P, and Madhavarapu M. 2013. A single centre prospective study of liver function tests in post liver transplant patients. *Indian Journal of Clinical Biochemistry* 28:38-45 DIO 10.1007/s12291-012-0245-4

Neuberger J, Portmann B, Macdougall BR, Calne RY, and Williams R. 1982. Recurrence of primary biliary cirrhosis after liver transplantation. *New England Journal of Medicine* 306:1-4 DIO 10.1056/nejm198201073060101
Schoning W, Schmeding M, Ulmer F, Andert A, and Neumann U. 2015. Liver Transplantation for Patients with Cholestatic Liver Diseases. *Viszeralmedizin* 31:194-198 DIO 10.1159/000431017

Selmi C, Bowls CL, Gershwin ME, and Coppel RL. 2011. Primary biliary cirrhosis. *Lancet* 377:1600-1609 DIO 10.1016/s0140-6736(10)61965-4

Shah RA, and Kowdley KV. 2019. Current and potential treatments for primary biliary cholangitis. *Lancet Gastroenterol Hepatol*. DIO 10.1016/s2468-1253(19)30343-7

Sun CK, Chen CL, Concejero AM, Wang CC, Wang SH, Liu YW, Yang CH, and Yong CC. 2011. Liver transplantation for primary biliary cirrhosis in a hepatitis endemic region: a single-center Asian experience. *Clinical Transplantation* 25:47-53 DIO 10.1111/j.1399-0012.2010.01288.x

Vera A, Contreras F, and Guevara F. 2011. Incidence and risk factors for infections after liver transplant: single-center experience at the University Hospital Fundacion Santa Fe de Bogota, Colombia. *Transplant Infectious Disease* 13:608-615 DIO 10.1111/j.1399-3062.2011.00640.x

Wojcicki M, Milkiewicz P, and Silva M. 2008. Biliary tract complications after liver transplantation: a review. *Digestive Surgery* 25:245-257 DIO 10.1159/000144653

Zhang W, Wang M, Xie HY, Zhou L, Meng XQ, Shi J, and Zheng S. 2007. Role of reactive oxygen species in mediating hepatic ischemia-reperfusion injury and its therapeutic applications in liver transplantation. *Transplantation Proceedings* 39:1332-1337 DIO 10.1016/j.transproceed.2006.11.021

**Figure legends**

**Fig. 1** Overall survival rate of 69 patients of PBC after liver transplantation. Overall survival rate
was 98.2% at 1 year, 94.2% at 3 years. PBC, primary biliary cirrhosis.

Fig. 2 APRI greater than 2 had a shorter overall survival.

Fig. 3 The relapse rates of PBC was 3.5% at 1 year, 8.1% at 3 years, and 21.8% at 5 years after transplantation.

Fig. 4 Comparison of the rate of recurrent PBC among different age groups at liver transplantation. Aged 48 years or younger had a high relapse rates of PBC.

Fig. 5 The curves of median liver function in 62 liver transplant patients changed posttransplantation. (a) AST and ALT; (b) ALP and GGT; (c) TBIL and DBIL; (d) ALB.
Table 1 (on next page)

Baseline characteristics
### Table 1: Baseline characteristics

|                          | No.(percent) or median(range) |
|--------------------------|------------------------------|
| Age(Y)                   | 55(39-67)                    |
| Gender                   |                              |
| Female                   | 60(87.0%)                    |
| Male                     | 9(13.0%)                     |
| Follow-up period(months) | 32.0(0.5-107)                |
| APRI                     | 2.26(0.11-42.22)             |
| MELD                     | 19(6-31)                     |
| Updated Mayo risk score  | 9.53(4.34-12.44)             |
| Child-pugh grade         |                              |
| B                        | 26(37.7%)                    |
| C                        | 43(62.3%)                    |
| Preoperative liver function |                          |
| AST (IU/L)               | 75(15-513)                   |
| ALT (IU/L)               | 45(6-229)                    |
| ALP (IU/L)               | 186.5(54-732)                |
| GGT (IU/L)               | 93.5(14-779)                 |
| TBIL (mg/dl)             | 9.83(0.41-41.6)              |
| ALB (g/dl)               | 3.0(2.3-4.4)                 |

APRI, aspartate aminotransferase-to-platelet ratio index; MELD, model for end-stage liver disease score; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; TBIL, total bilirubin; ALB, albumin.

Normal range: AST 13-35, ALT 7-40, ALP 35-125, GGT 7-45, TBIL 0.40-1.75, ALB 4.0-5.5.
Table 2 (on next page)

Postoperative complications
Table 2: Postoperative complications

| Category                      | Count | Percentage |
|-------------------------------|-------|------------|
| Infection complications       | 63    | 63%        |
| Respiratory infection         | 30    |            |
| Biliary infection             | 13    |            |
| Bacteremia                    | 6     |            |
| Urinary tract infection       | 5     |            |
| Abdominal infection           | 4     |            |
| Skin or tissue infection      | 1     |            |
| Gastrointestinal infection    | 1     |            |
| Thoracic infection            | 1     |            |
| Cytomegalovirus infection     | 1     |            |
| Biliary complications         | 21    | 21%        |
| Ischemic-type biliary lesions | 10    |            |
| Anastomotic stricture         | 7     |            |
| Bile leakage                  | 3     |            |
| Biloma                        | 1     |            |
| Vascular complications        | 5     | 5%         |
| Hepatic artery thrombosis     | 3     |            |
| Portal vein thrombosis        | 2     |            |
| Rejection                     | 1     | 1%         |
| Chronic rejection             | 1     |            |
| Other complications           | 10    | 10%        |
| Osteoporosis                  | 5     |            |
| De novo hepatitis B infection | 3     |            |
| Diabetes mellitus             | 2     |            |
Figure 1

Overall survival rate of 69 patients of PBC after liver transplantation.

Overall survival rate was 98.6% at 1 year, 95.1% at 3 years. PBC, primary biliary cirrhosis.
Figure 2

Patient survival rate according to the APRI before liver transplantation.

APRI greater than 2 had a shorter overall survival
Figure 3

Rate of relapse of PBC after liver transplantation.

The relapse rates of PBC was 3.5% at 1 year, 8.1% at 3 years, and 21.8% at 5 years after transplantation.
Figure 4

Comparision of the rate of recurrent PBC among different age groups at liver transplantation.

Aged 48 years or younger had a high relapse rates of PBC.
Number at risk

| Age | 0  | 1 year | 2 years | 3 years | 4 years | 5 years |
|-----|----|--------|---------|---------|---------|---------|
| <48 | 14 | 12     | 8       | 6       | 6       | 3       |
| ≥48 | 55 | 43     | 31      | 22      | 12      | 6       |

Log-rank test p=0.002
Figure 5

The curves of median liver function in 62 liver transplant patients changed posttransplantion. (a)AST and ALT; (b)ALP and GGT; (c)TBIL and DBIL; (d)ALB.

(a)AST and ALT; (b)ALP and GGT; (c)TBIL and DBIL; (d)ALB.
